Evolus, Inc. (EOLS)

Evolus, Inc.'s stock price has declined approximately 40.91% in the past six months. In Q2 2025, the company reported a loss and lagged revenue estimates, with a downward revision of 2025 net revenue guidance and a decrease in Jeuveau sales. Earlier, in late 2024, the stock tumbled following weak Q3 earnings. Evolus reported positive data from a pivotal study of Evolysse Sculpt in August 2025 and is scheduled to participate in the Stifel Healthcare Conference in November 2025. Insider trading activity has shown both buys and sells by company executives and directors.

Evolus, Inc. has indicated that its growth moderation signifies an alignment with "traditional seasonality" in the aesthetic market. The company anticipates this trend to persist through the first half of the year, suggesting that demand for its products and services experiences seasonal fluctuations.

Evolus, Inc. is a performance beauty company in the medical aesthetics market, headquartered in Newport Beach, California, operating in the Health Technology and Health Care sectors. Its primary product is Jeuveau® (prabotulinumtoxinA-xvfs), used for improving glabellar lines, and is also expanding its product portfolio with the Evolysse™ line of injectable hyaluronic acid (HA) gels. The company emphasizes a customer-centric approach and a digital-first commercial model.

Evolus, Inc. is headquartered in Newport Beach, California, USA. Jeuveau® is sold in the United States, while Nuceiva® is available in Canada and Great Britain. The company plans to expand into Germany, Austria, and Australia, with further expansion into additional European countries and Australia.

There are indications of challenges to Evolus, Inc.'s brand reputation, with decreased consumer sentiment impacting Jeuveau sales in Q2 2025. Despite this, analyst sentiment towards Evolus is generally optimistic, with a consensus of "Strong Buy" ratings. The company aims to differentiate itself through a customer-centric business model, an innovative digital platform, and by prioritizing physician partnerships and patient satisfaction.

Evolus, Inc.'s ownership structure includes institutional, retail, and individual investors. Institutional investors hold a significant portion of the company's stock, ranging from approximately 76.64% to 90.14%. Major institutional holders include BlackRock, Inc., The Vanguard Group, Inc., Perceptive Advisors LLC, Frazier Life Sciences Management, LP, and Soleus Capital Management, L.P. Medytox Inc. owns 16.45% of the company's shares, and Alphaeon 1 LLC also holds a notable stake.